Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020

The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. In a Jan. 2 research note, ROTH Capital Partners analyst Jonathan Aschoff reported that he is assuming coverage on VBL Therapeutics (VBLT:NA...
Streetwise Reports | January 9, 2020 |

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. In a Sept. 26 research note, Dawson James Securities analyst Jason Kolbert reported that IsoRay Inc. (ISR:NYSE.MKT) launched a new marketing campaign call...
Streetwise Reports | October 1, 2019 |

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. This morning, Genprex Inc. (GNPX:NASDAQ) , which "utilizes a...
Streetwise Reports | January 22, 2020 |

Gold – The Bull Is Alive!

Since 3rd of September gold and the SPDR Gold Trust ETF (NYSEARCA: GLD ) are consolidating and correcting. But so far bulls can hold prices above US$1,483. Even though commitment of trades numbers for the gold market are looking terrible, the bull still seems to be alive and k...
Midas Touch Consulting | October 1, 2019 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

Malevolent Microbes

There is a local casino just "up the road" from where we reside that we visit (once in a blue moon), small sums of pocketed cash in hand, to play a few favored slot machines to see if we can defy the house odds and come home winners. Called The Great Blue Heron Casino, we...
Streetwise Reports | January 28, 2020 |